Clinical Results after High-Dose Intensity-Modulated Radiotherapy for High-Risk Prostate Cancer

Abstract EN

Purpose.

Patients with high-risk prostate cancer (PC) can be treated with high-dose intensity-modulated radiotherapy (IMRT) and long-term androgen deprivation (AD).

In this paper we report on (i) late toxicity and (ii) biochemical (bRFS) and clinical relapse-free survival (cRFS) of this combined treatment.

Methods.

126 patients with high-risk PC (T3-4 or PSA >20 ng/mL or Gleason 8–10) and ≥24 months of followup were treated with high-dose IMRT and AD.

Late toxicity was recorded.

Biochemical relapse was defined as PSA nadir +2 ng/mL.

Clinical relapse was defined as local failure or metastases.

Results.

The incidence of late grade 3 gastrointestinal and genitourinary toxicity was 2 and 6%, respectively.

Five-year bRFS and cRFS were 73% and 86% respectively.

AD was a significant predictor of bRFS (P=0.001) and cRFS (P=0.01).

Conclusion.

High-dose IMRT and AD for high-risk PC offers excellent biochemical and clinical control with low toxicity.